

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 February 2008 (14.02.2008)

PCT

(10) International Publication Number  
WO 2008/019303 A3

(51) International Patent Classification:  
A61K 38/12 (2006.01) C07K 5/12 (2006.01)

(21) International Application Number:  
PCT/US2007/075146

(22) International Filing Date: 3 August 2007 (03.08.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
11/499,844 4 August 2006 (04.08.2006) US  
11/832,893 2 August 2007 (02.08.2007) US

(71) Applicant (for all designated States except US): ENANTA  
PHARMACEUTICALS, INC. [US/US]; 500 Arsenal  
Street, Watertown, MA 02472 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MOORE, Joel, D.  
[US/US]; 64 Cliffe Avenue, Lexington, MA 02420 (US).  
TANG, Datong [CN/US]; 35 Court Street, Newton, MA  
02458 (US). OR, Yat, Sun [US/US]; 169 Fayette Street,  
Watertown, MA 02472 (US). WANG, Zhe [US/US]; 67  
Westwoods Blvd., Hockessin, DE 19707 (US).

(74) Agents: NAKAJIMA, Suanne et al.; Elmore Patent Law  
Group, P.C., 209 Main Street, N. Chelmsford, MA 01863  
(US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,  
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,  
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,  
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,  
ZM, ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,  
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
30 October 2008

(54) Title: PYRIDAZINONYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS



(I)

(57) Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

WO 2008/019303 A3

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US07/75146

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC: **A61K 38/12( 2006.01);C07K 5/12( 2006.01)**

USPC: 514/10,11;530/317  
 According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 514/10,11; 530/317

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 STN (reg.zcap) core structure of formula (I)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/072243 A2 (ENANTA PHARMACEUTICAL, INC.) 26 August 2004 (26.08.2004), entire document	1
A	US 20050153877 A1 (MIAO et al) 14 July 2005 (14.07.2005) entire document	1-3, 5-11, 13-16
A	US 2004/0180815 A1 (NAKAJIMA et al) 16 September 2004 (16.09.2004) entire document	1-3, 5-11, 13-16

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means.	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 14 July 2008 (14.07.2008)	Date of mailing of the international search report <b>19 AUG 2008</b>
--	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Authorized officer <i>Andrew D. Kosar</i> Andrew D. Kosar Telephone No. (571)272-1600
---	--

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US07/75146

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: 4 and 12  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Claims 4 and 12 reference the specification and are incomplete claims, thus no meaningful search or opinion can be formed.
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.
  3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
  4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
- Remark on Protest**
- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
  - The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
  - No protest accompanied the payment of additional search fees.